Sufficient strategies for travel quarantine and testing

Chad R. Wells[1], Jeffrey P. Townsend[2,3,4,5]*, Abhishek Pandey[1], Meagan C. Fitzpatrick[7], William Crystal[6], Alison P. Galvani[1,3]

[1]Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut 06520, USA
[2]Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut 06510, USA
[3]Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut 06525, USA
[4]Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06511, USA
[5]Program in Microbiology, Yale University, New Haven, Connecticut 06511, USA
[6]Yale College, New Haven, CT 06520
[7]Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, 21201, USA

These authors contributed equally: Chad R. Wells and Jeffrey P. Townsend

Keywords: Coronavirus; quarantine; travel; disease control; testing; border closure

*Corresponding author: Jeffrey.Townsend@Yale.edu

Abstract

A major policy tool used by governments during the COVID-19 pandemic has been the imposition of quarantine and testing requirements on international travel, extending even to the extreme approach of closing national borders. However, both approaches have far-reaching socioeconomic implications. Therefore, we evaluated the implications of quarantine and testing compared to the reductions achieved by border closure on in-country imminent transmission based on country-specific prevalence, daily incidence, vaccine coverage, immunity, age-demographics, and travel flow. We considered travel quarantines of 0–14 days with and without RT-PCR or antigen testing for COVID-19 in 31 European countries. Our analysis demonstrates that for the vast majority of origin-destination country pairs, there are combinations of short-duration quarantine and testing that are as effective as border closure. Furthermore, for most origin-destination country pairs, travel with testing and no quarantine will reduce imminent in-country transmission more than would border closure. We find that the duration of quarantine is predominantly influenced by country prevalence and quantity of travel. With higher prevalence in the origin country compared to the destination country, the minimum duration of quarantine increases from zero to beyond fourteen days (at which point border closure would likely be practical). Asymmetry in travel flow can also cause an increase or decrease of infections within the destination country, respectively resulting in longer and shorter quarantines. We apply the same framework to genetic variants of concern to limit their spread as a consequence of travel; the widespread variant of concern B.1.1.7 yields similar sufficient quarantine and testing regimes, whereas the lower-frequency, geographically heterogeneous 501Y.V2 variant requires longer, more specific quarantines. We show that adaptation of our analytical framework to the European Union traffic-light country risk stratification provides a simplified policy tool. Lastly, we examined the effect of travel quarantine and testing or border closure policy on hospitalization in the destination country. We find that hospitalization rates in the destination country are far more sensitive to changes in the vaccine coverage than on the duration of the travel quarantine or the country of origin. Our analysis provides rigorous guidelines enabling travel between most countries during early and late phases of pandemic disease.

Keywords: SARS CoV-2, RT-PCR test, antigen test, tourism, travel quarantine

Introduction

Quarantine of travelers to prevent the importation of disease has been a cornerstone of efforts to prevent infectious disease since at least the fourteenth century [1]. Ongoing efforts to limit the importation and global dissemination of COVID-19 cases have included the imposition of strict national border control measures. These restrictions aid in mitigating the appearance of new clusters of cases within the country [2]; those who do enter the country are typically required to undergo an extended quarantine. However, border restrictions and extended quarantines have carried a large economic burden, while having little effect as the pandemic progressed [3–5]. Even during the early stages of the COVID-19 pandemic, some border closures only minimally delayed the global spread of SARS CoV-2 [6]. Enabling safe travel between countries and reducing the duration of travel quarantine without increasing the country-specific infection rate would aid in the rejuvenation of the international economy.

Questions regarding the efficacy of travel quarantine and testing have recently been brought to the fore by the emergence of variants of concern of SARS CoV-2 (VOCs), some of which are more transmissible than previous strains [7]. Currently there is uncertainty regarding the extent of protection provided by natural and vaccine acquired immunity against each VOC. Concern regarding these variants has spurred the imposition of long quarantines, extensive COVID-19 and VOC testing, and renewed border closures to prevent VOCs from entering their country [3]. Impeding the establishment of VOCs with appropriate travel quarantine strategy would provide time for vaccine coverage to be scaled up sufficiently to limit overall transmission. However, it is unclear how effectively travel quarantine and testing strategies can reduce the seeding of new VOC cases. Therefore, knowledge of the potential suppressive effects of travel quarantine and testing on prevalence of known VOCs is important to limiting resurgence of the disease and must be incorporated to design country-specific and individualized travel quarantine strategies.

Quarantine duration has traditionally been set with an aspiration that it is long enough to ensure prevention of post-quarantine transmission with or without testing [8]. Such a goal is reasonable when entering a country with zero or near-zero prevalence of disease [9], or for a traced contact with a high chance of being infected. However, travelers are typically far less likely to have been infected than traced contacts; if disease prevalence in their origin country is not substantially elevated in comparison to their destination, then their transmission risk is presumably similar to residents of

the destination country who are following the same country-specific public health precautions. Because international travel is generally considered a desirable activity for diverse socioeconomic reasons, it would be reasonable for border controls in these global pandemic scenarios to have the objective not of preventing any transmission of pandemic disease by travelers—which, after all, is typically exchangeable in impact with transmission by residents—but instead of ensuring that travel does not cause a net increase in disease compared to border closure or complete prohibition of travel. Because sufficient quarantine and testing at the border can decrease in-country post-quarantine transmission to arbitrarily low levels [8], and infected individuals departing the country diminish in-country transmission, such a balance should be determinable.

Here we integrate analytical approaches for the calculation of post-quarantine transmission [8] with a model of country-specific imminent infections to identify strategies of travel quarantine and testing enabling travel and supporting economy and commerce—strategies of quarantine and testing that will not increase their country-specific infection rate compared to a strategy of complete border closure. For each country pair of 31 countries in Europe, we quantify the duration of travel quarantine that maintains imminent infections that is equivalent to or improves upon infections arising under a strict border closure using an infectivity profile and longitudinal diagnostic test sensitivity [8], incorporating the travel flow between countries, country-specific age structure, seroprevalence, and vaccine coverage and efficacy. We examine the consequences of travel quarantine and testing and vaccination including age-specific efficacy on the hospitalization rate. Lastly, we evaluate the policy implications of sufficient quarantine and testing strategies for the EU traffic-lights stratification of COVID-19 infection risk.

Results

Conservatively assuming long-term stays (i.e., prevalence in travelers was assumed to rise to the prevalence in the country visited by the time of return) and parameterizing with data specifying a basic reproductive number of 2.5 [8], age-dependent symptomatic disease [10], vaccine efficacy [11] and country-specific coverage [12], an incubation period of 8.29 days [8,13,14], and isolation upon symptom onset [8], we derived theory enabling the calculation of sufficient quarantines— the minimum travel quarantine duration with and without RT-PCR and antigen testing such that the number of imminent infections (i.e., new infections generated from the daily net change in infected individuals) remains

equivalent or lower than that estimated under border closure (**Fig. 1; Methods**). For each available pairing of 31 countries, we defined the country to which individuals travel as the destination country, and the country of departure as the origin country. Utilizing reported daily incidence [15], reported vaccine coverage [12], country-specific age demographics [16], and 2019 travel flow [17–27] for each pair (**Table S1–S2**), we calculated a sufficient quarantine as the minimum travel quarantine duration with an RT-PCR test conducted on exit at which daily imminent infections would not exceed those in the destination country if travel were not permitted. If the sufficient quarantine duration exceeded 14 days, we indicated prohibition of travel by the destination country from the origin country. Furthermore, we also classify countries based on the European Union (EU) system for COVID-19 travel restrictions [28]. The system stratifies countries based on reported case load over the last two weeks: i) Green, < 25 cases per 100,000 ii) Amber, 25–150 cases per 100,000; iii) Red, 150–500 cases per 100,000; and iv) Dark Red, > 500 cases per 100,000.

Figure 1. Model schematic diagram for imminent infections and travel quarantine. With travel between country A (red) and country B (blue), the travel quarantine specified by country A is dependent on the intensity of infection in both country A and B, the number of residents leaving country A for country B, the number of travellers entering country A from country B, the number of residents returning to country A, and the number of travellers from country B returning to country B. In the most general instantiation of our model, the minimum duration of travel quarantine is dependent on the number of daily travellers from country A to country B, n_{AB}, the number of daily travellers from country B to country A, n_{BA}, the country-specific prevalence of non-isolated infections ϱ, country-specific immunity φ, the number of travellers from country B abroad in country A, n_B, the number of citizens of A who are non-travellers and not quarantined, N_A, daily fractional incidence, c. The amount of remaining transmission (R_A, R_V, $R_{Qv, V}$) is calculable based on virus- or variant-specific properties and the temporal infectivity and test sensitivity [8].

Country-specific quarantines

Evaluation on the basis of our full model with all parameters as of April 12, 2021 yielded quarantine and testing regimes sufficient to enable travel without increasing in-country transmission (**Fig. 2**). By following country-specific travel quarantine strategies that are individualized for origin and destination pairs, we found that, for the countries considered, travel can be allowed among most pairings without increasing the imminent infections in the destination country (**Fig 2**, **Fig S1**). Countries with lower prevalences of disease tended to require more stringent regimes of quarantine and testing (**Fig. S2**). For example, as of April 12, the United Kingdom (UK) was classified in Amber EU travel status and exhibited the lowest case burden per capita among the 31 European countries studied. We found that quarantine durations ranging between zero and five days would result in fewer imminent infections in the UK than would closed borders (**Fig. 2A**). Portugal was also Amber status; sufficient quarantine durations for Portugal ranged between 2–7 days, including quarantines of at least six days for travelers from high-prevalence Czechia, Poland, and Hungary (**Fig. 2B**). Red EU travel status countries Belgium and Italy exhibited intermediate incidence and sufficient quarantine durations of zero to three days and zero to four days respectively (**Fig. 2C–D**). Dark-red EU travel status countries Cyprus and Hungary—with high prevalence—require quarantine durations of zero to five days and 0 days respectively, with prohibition of travel from the UK and Norway into Cyprus (**Fig. 2E–F**). In general, we found that the recommended duration of travel quarantine increases with the ratio of the prevalence for the origin country relative to the destination country (**Fig. 2G**). In particular, destination countries with low prevalence (Amber status) should have longer quarantine durations with a median of three days, whereas destination countries with high prevalence (Dark Red status) require quarantine durations with a median of zero days. Similarly, the duration of travel quarantine required for travellers from origin countries with high prevalence (Dark Red status; median two days) was longer than individuals departing from origin countries with moderate prevalence (Amber status; median zero days).

In addition to prevalence of disease, travel volume has a significant impact on quarantine and testing regimes that are sufficient to enable travel without increasing in-country transmission (**Fig. S2**). For instance, a comparison of Belgium and Italy—both Red status—reveals that quarantines to visit Italy tend to need to be longer to be sufficient, not only because of differences in prevalence, but also because of differences in typical travel volume arising from the popularity of Italy as a travel destination (**Fig. 2C–D**). The effect of travel volume is even stronger in a comparison of quarantine durations for two Dark Red status countries, Cyprus and Hungary (**Fig. 2E–F**). Travel from the UK to Cyprus is

historically high; consequently, prohibition of travel for visitors from the UK would be required to ensure transmission within Cyprus is not increased by travel from the UK. For a few destination countries, we found that even a travel quarantine duration of 14 days would be insufficient to keep imminent infections equivalent to or lower than that achieved by prohibition of travel (**Fig. 2G; Fig. S1**). This result can arise when there is substantial asymmetry in the number of travellers abroad. For example, the average duration of stay for visitors to Turkey is 9.9 days [27], which is longer than 97% of stays in any of the other countries. In addition, substantially more travellers enter Turkey than residents of Turkey travel out. Large numbers of visitors staying for long durations results in a large number of travellers in the country and few residents abroad, leading to serious challenges in devising a sufficient quarantine and testing procedure to maintain open travel at typical levels.

We further evaluated the effect of opening borders for travel on hospitalization within the destination country. We calculated the two-week hospitalization rate per 100,000 for each of the country pairings assuming a zero-day travel quarantine with an RT-PCR test, an antigen test, or no test. Regardless of testing, we found that there was negligible change in the short-term hospitalization rate for a destination country—a result that held true irrespective of the origin country's prevalence (**Fig 3A; Figs. S3–S6**). Imposing a very long travel quarantine of 14 days with an RT-PCR test on exit only nominally reduced in the country-wide hospitalization rate (**Fig 3B; Figs. S7–S10**)—with no testing, the maximum reduction in the hospitalization rate was 8.8%, with 84.3% of all country pairs experiencing less than a 1% reduction. With RT-PCR testing on exit, the maximum reduction in hospitalization rate was 5.6%, with 92% of all country pairs experiencing less than a 1% reduction.

Figure 2. The estimated minimum duration of travel quarantine for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with an RT-PCR test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25–150 cases per 100,000; Red, 150–500 cases per 100,000; and Dark Red, > 500 case per 100,000. We consider travel quarantine durations of zero-days (white) to no travel (dark purple with "X", i.e., sufficient travel quarantine would exceed 14 days) for **A**) Portugal, **B**) the United Kingdom, **C**) Finland, **D**) Greece, **E**) Italy, **F**) Czechia, and **G**) 20 of 31 countries analyzed (*cf.* **Fig. S1**). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). For quarantine durations of 1 day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Figure 3. The impact of travel quarantine on the two-week hospitalization rate per 100,000. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine **A**) the two week hospitalization rate (orange gradient) from the estimated imminent infections for a zero-day travel quarantine with a

RT-PCR test on exit and **B**) the relative reduction in the hospitalization rate (green gradient) when the quarantine is extended to 14 days. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. For quarantine durations of 1 day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Variants of concern

In our base case scenario (**Fig. 2**), we evaluated a general goal of eliminating the impact of travel on all imminent infections, and did not distinguish among genetic variants or their properties. As variants of concern (VOC) become known, they can be incorporated into a general analysis or analyzed individually. Specifying 100% cross-immunity and no reduction in vaccine efficacy, we evaluated the impact of VOCs B.1.1.7 [29] and 501Y.V2 [30] within the destination and origin countries, based on their estimated circulation [31], on the minimum duration of travel quarantine with the goal of no net increase in the incidence of VOCs or wild-type (**Fig. 4** and **Fig. S11**). Preventing both increased general transmission and transmission of VOCs by international travel would require lengthy quarantines and more travel prohibitions compared to a homogeneous evaluation (**Fig. 4** vs **Fig. 2G** and **Fig. S11** vs **Fig. S1**). The sufficient duration of travel quarantine increased substantially (median of six days vs median of zero days; **Fig. S11** vs **Fig. S1**).

Because the effect of travel restriction on in-country hospitalization is so small (**Fig. 3**), it may be warranted to focus travel policy on the prevention of additional in-country infection by specific variants of concern, incorporating any additional knowledge about infectiousness level or duration and test sensitivity. As of April 12, the highly infectious B.1.1.7. variant was fairly widespread across much of Europe. Therefore, among countries with surveillance enabling estimation of the variant frequency, sufficient quarantine and testing is similar for this variant to that determined for general transmission (**Fig. 2G** vs. **Fig. 4A**). In contrast, the 501Y.V2 VOC was at relatively low frequency in most European countries, with much greater variance in prevalence across European countries. Consequently, sufficient quarantine and testing would be more extreme and more distinct for this variant than that determined for general transmission or for B.1.1.7 (**Fig. 4B** vs. **Fig. 2G** and **Fig. 4A**). Combining concern for two variants leads to sufficient quarantines for each origin-destination pair that are the maximum of those deemed sufficient for each variant (**Fig. 4C**).

Consequently, incorporating additional VOCs into the goal of assuring no additional infection due to travel leads to increasingly longer quarantines and significant prohibition of travel (**Fig. 4D**).

Figure 4. The estimated minimum duration of travel quarantine for specified country pairs that reduces imminent infections to be equivalent to travel prohibition when considering variants of concern. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, percentage of variants of concern, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine (colour gradient) that should be stated by the destination country for individuals arriving from the origin country when considering **A**) transmission of the variant of concern B.1.1.7., **B**) transmission of the variant of concern 501Y.V2, **C**) transmission of the variants of concern B.1.1.7 and 501Y.V2, and **D**) general transmission and transmission of the variants of concern B.1.1.7. and 501Y.V2. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150–500 cases per 100,000; and Dark Red, > 500 case per 100,000. For travel quarantine durations of 1 day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Generalization of travel quarantine

We next calculated sufficient quarantines based on the input used by the EU COVID risk classification system. Setting population sizes, natural immunity, vaccine coverage, travel duration, and travel flow between countries to be the average of obtained data on the countries analyzed, we found that for origin countries at equal or lower COVID status than the destination country, a zero-day travel quarantine with RT-PCR test is equivalent to or better than travel prohibition (**Fig. 5**). As the ratio of the cases in the origin country to the destination country increases, the specified duration of travel quarantine increases (**Fig. 5**). For origin countries with a greater number of infections per capita over the last two weeks than the destination country, the median duration of travel quarantine with an RT-PCR test on exit was three days, and durations ranged from one to six days (**Fig. 5A**).

Because testing approaches vary as well as quarantine duration, we compared sufficient travel quarantine durations under alternative strategies of no testing, RT-PCR conducted on exit, a rapid antigen test on exit, and a rapid antigen test on both entry and exit. Regardless of testing approach, discrete tier categorization as opposed to quantitative calculation led to sufficiency of zero-day travel quarantine in any origin-destination pair for which the destination status was equivalent or worse than the origin status (**Fig. 5**; cf. **Fig. 2G**). Among origin countries with more infections per capita than the destination country, the median sufficient quarantine duration with no test was five days, and duration ranged from two to nine days (**Fig. 5B**). With an RT-PCR test on exit from quarantine, the sufficient quarantine duration declined by a median of two days, and the decrease in duration ranged from one to three days (**Fig. 5A**). Switching to less-sensitive but inexpensive and logistically flexible rapid antigen tests yields results nearly identical to those determined using RT-PCR testing on exit (**Fig. 5C** vs. **Fig. 5A**); only when the status of the destination country is Green and the status of the origin country is Dark Red does the sufficient quarantine duration exceed the RT-PCR test on exit duration by one day. Adding an antigen test on entry to quarantine as well as the antigen test on exit eliminated that difference (**Fig. 5A,D**). We also quantified the effects of these alternative testing strategies in the context of our much more richly parameterized country-pair analysis (**Fig. S12–S14**), and found that these trends were roughly consistent with the results obtained from a tier-based analysis (**Fig. S15**). Specifically, when the origin country was assigned lower-risk status than the destination country, the durations of quarantine for travelers from the origin country were equal to the median for equivalent country pairs in the tier-based analysis (**Fig. S15**). When the origin country was assigned higher-risk status, the tier-based analysis exhibited the same increasing trend of quarantine duration with increasing EU risk status as did the country-pair analysis.

The greatest discrepancy regarded the strategy of no testing for an Amber status destination country and Dark-Red status origin country (**Fig. S15B**), wherein the median from the country-pair analysis was as much as three days longer than that specified from the tier-based analysis.

Figure 5. Duration of travel quarantine for specified country pairs sufficient to prevent additional imminent infection due to travel, using prevalence associated with European Union traffic-light categorization of COVID-19 risk. Sufficient quarantine durations (colour gradient) are calculated including **A**) an RT-PCR test on exit, **B**) no testing, **C**) a rapid antigen test on exit, and **D**) a rapid antigen test on both entry and exit, specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, average European age structure, 17.6% vaccine coverage, and 18.8% natural immunity, for origin countries whose EU traffic-light status is Green (25 cases per 100,000), Amber (150 cases per 100,000), Red (500 cases per 100,000), or Dark Red (1,000 cases per 100,000). For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result and no delay in obtaining the rapid antigen test. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

We calculated the hospitalization rate per 100,000 population for vaccine coverage ranging from 0% to 100% within both the origin and destination country under the minimum specified travel quarantine duration (**Fig. 6**). For countries interested in setting quarantine duration based on hospitalization rates, instead of imminent infections, we considered an alternative threshold for the minimum travel quarantine that requires the hospitalization rate to be equivalent or lower than the hospitalization rate when there is no vaccination and no travel, assuming the destination country is in Green status. For origin countries that are not assigned Green status, this travel quarantine duration is shorter than that required under the criteria based on imminent infections. We found that a longer travel quarantine based on the imminent infection criteria provides a minimal decrease in the hospitalization rate when compared to zero-day travel quarantine (**Fig. 6**).

Figure 6. Expected hospitalization rate in a Green-light destination country across varying vaccine coverage and travel quarantine durations. We calculated the projected two-week hospitalization rate for vaccine coverages between 0% and 100% (in both origin and destination), for a destination country whose traffic-light status is Green (25 cases per 100,000) visited by people from an origin country whose traffic-light status is Dark Red (1,000 cases per 100,000) with an RT-PCR test quarantine was zero days (light blue), six-days (black) or 14 days (light green) combined with an RT-PCR test on exit. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Alternative diagnostic sensitivity curve for the RT-PCR test analysis

We examined the impact of an RT-PCR test on exit with an alternative temporal diagnostic sensitivity curve from Wells et. al. [8] on the minimum duration of quarantine (**Figs. S16–S19**). In the country-paired analysis, the median sufficient duration of quarantine with an RT-PCR test on exit was equivalent to the median duration from our baseline analysis. In addition, the sufficient duration of quarantine was shorter (by at most three days) than that in our baseline for 37% of the country pairings. In our tier-based analysis, the median sufficient duration of quarantine with an RT-PCR test on exit decreased from three days to two days, when the origin country was assigned higher-risk status. Additionally, the sufficient quarantine duration was at most two days shorter when compared to our baseline.

Discussion

Here we have evaluated strategies of travel quarantine and testing that are sufficient to ensure that in-country imminent transmission is no greater than would occur under prohibition of travel. We demonstrated that these strategies can be informed by prevalence, daily incidence, vaccine coverage, immunity, age-demographics, and travel flow, specifying quarantines for each destination that are specific to travel origin. Our analysis indicates that for nearly half of the country pairs, no quarantine or test is necessary to prevent increased imminent in-country transmission from travel, and for the majority, a test with no quarantine is sufficient. For many other origin-destination pairs, a travel quarantine of a few days with testing will suffice. The duration of travel quarantine specified by the destination country is influenced mainly by the relative prevalence of disease between the two countries, the number travellers, and the asymmetry of travel. Genetic variants of concern can be accounted for as well; depending on how widespread the variant is, sufficient quarantine and testing to prevent travel from increasing imminent in-country VOC transmission can be very similar to the corresponding general case. However, when VOCs are infrequent and prevalence is heterogeneous on the international scale, sufficiency can be very different from that specified for generalized transmission, and may require long durations of quarantine and testing or merit prohibition of travel. Two-week hospitalization rates in a destination country were found to be insensitive to travel quarantine duration and the country in which travellers have departed from—and, in general, are vastly more sensitive to levels of vaccination.

Implementing travel quarantine and testing policies that are specific to many input parameters, dependent on country of origin as well as destination—and that change dynamically as waves of the pandemic strike and recede—is logistically challenging. Indeed, some countries have specified a single quarantine duration for any traveller entering their country [32,33]. However, such a policy may be unduly restrictive—or in some cases may not be restrictive enough. An intermediate approach is to simplify input parameters and discretize country classification in accordance with current policy implementations, such as the incidence-based EU Traffic Light system. By considering European averages for other parameters, we demonstrated the feasibility of mapping our more highly parameterized approach to the EU Traffic Light system. The agreement between our highly parameterized country-pair specific results and the results that we obtain mapping it to the prevalence-only EU Traffic Lights categories is imperfect at best. However, it provides analytical justification for policy decision-making that can otherwise be highly politicized rather than motivated by considerations of public health within the country.

Our analyses have focused on imminent infection in comparison to prohibition of travel, on the justification that it seems challenging to justify the imposition of quarantine and testing regimes that reduce in-country transmission more than would prohibition of travel. Essentially, they are maximal quarantine and testing regimes that are justifiable. However, it is essential to keep in mind that these sufficient regimes do not evaluate cost-effectiveness or direct public health outcomes. Whether quarantines of the durations specified here are worthwhile from a public health perspective requires additional consideration of the public health outcomes of quarantine and testing regimes. For instance, high rates of hospitalization can overwhelm the healthcare infrastructure in a country. Thus, policy makers may want to ensure that the hospitalization rate remains manageable by specifying travel quarantines. We found that hospitalization rates based on imminent infections in the destination country were minimally influenced by where travellers are coming from or even by quarantine duration. This low impact result is due to the relatively small numbers of travellers when compared with the resident population and the widespread infection characteristic of a fully emerged pandemic [34]. In this circumstance, travel quarantines make an almost trivial contribution toward total in-country imminent infections and a proportionately small contribution toward hospitalization rate. Specifying sufficiency of quarantine by country risk status aligned with pre-vaccination rollout hospitalization thresholds (as opposed to pre-vaccination rollout imminent infection thresholds), sufficient quarantine was often much shorter than when determined by the imminent infection threshold. Moreover,

rapidly diminishing public health returns of travel quarantines are consequent to the alleviation of hospitalization associated with age-structured vaccination. A balanced consideration of quarantine duration should come both from an understanding of the relative impact of travel on infection and on the public health consequences of infections.

Our analysis focuses on a pandemic that has already emerged globally, with few exceptions where the virus has been forestalled at a national [15] or geographic border [35]. Over the majority of the pandemic, for instance, New Zealand has effectively maintained low COVID-19 case numbers [15]. Travel to New Zealand was restricted to citizens of New Zealand, who were only able to enter the country upon a negative test prior to departure, followed by a highly effective 14-day quarantine with two negative tests [8,36]. New Zealand aims to maintain closed borders with most of the globe until there is sufficient vaccine protection [36,37]. This strategy is consistent with our approach and is supported by our analytical calculations for a country with very low or zero reported daily fractional incidence. Indeed, our approach would indicate border closure by many countries early in the pandemic before global spread of infection—a closure that did not happen for a variety of geopolitical reasons, but also because of technology development and supply limitations that prevented rapid, widespread, global testing. Its informativeness is dependent on knowledge of the prevalence of disease, which even today can often be under-reported due to limited national and international health resources.

As the pandemic progresses, quarantine decisions may shift completely toward prevention of one or multiple variants of concern that are more transmissible or can escape natural and vaccine-mediated immunity. Recent studies have indicated that the new variants are at least 50% more transmissible than the wild-type and more virulent [7]. Higher transmissibility and higher potential to escape vaccine-mediated immunity are both serious public health threats that may justify imposition of highly restrictive quarantine and testing regimes, or even border closure. Just as in the early COVID-19 pandemic [38], it is possible with strong implementation to forestall variants of concern at the border, which dependent on their properties can yield tremendous public health benefits. Accurate identification of those properties is crucial, because attempting to forestall low-frequency variants of unknown significance would essentially entail complete border closure. Therefore, development of genomic surveillance for variants of concern, and approaches to rapidly and accurately assess their epidemic properties, should be a priority in a global pandemic, so that decision-making regarding imposition of variant-related border quarantine and testing can be informed and judicious.

Although we have applied our analysis at a national level—where border controls are typically strongest and easiest to impose—it is not limited to travel between countries. It can be applied to any distinct population that can be monitored for the entry and exit of travellers. As the size of the destination population of interest decreases, travel quarantine decisions can become increasingly sensitive to local fluctuations. Our analysis provides sufficient quarantines associated with international travel between countries. However the sufficiency of a 0-day quarantine for international travel between two countries does not sanction widespread local travel after arrival, which may lead to local infections where there were previously none. Widespread travel can result in rapid dissemination of the disease throughout the country, due to heterogeneity in local prevalence of disease. Thus, international quarantine and testing should not be considered a substitute for national policy preventing the spread of disease at a more localized scale within the country itself [39]. Our analytical approach provides the short-term impact of the travel quarantine measures in comparison to the current epidemic status of the country. Under the travel quarantine specifications calculated via our modeling framework, international travel economy between two countries can be equitably stimulated, such that the expected in-country transmission or hospitalization will be no worse than if the border between the two countries were closed. The long-term outcome of the global pandemic will be determined far more by the control measures that are put in place globally to limit community transmision, e.g. social distancing, mask wearing, contact tracing and case isolation, and vaccination.

As with many policy assessments, our quantification of sufficient travel quarantine and testing strategies is dependent on the successful implementation of measures taken, and can be undermined by non-compliance to quarantine. Imminent in-country infections will be increased by non-compliance. However, it should be kept in mind that non-compliance is increased by the stringency of the requirement, so that it is possible to achieve less by requiring more. For example, some patrons entering Canada opt not to comply with the stringent quarantine specified by the Federal Government [40–42]. For COVID-19, the first days of quarantine are often the most important to the prevention of transmission [8]. Consequently, disillusioned and abject lack of adherence to travel quarantine can lead to increased imminent infections within a destination country, as well as the potential for variants of concern to become established within the population. When the quarantine necessary is short, it can be disadvantageous to public health goals to require a longer quarantine than needed. Quarantine durations indicated by our analysis of 31 European countries are shorter than the early-pandemic consensus for 14-day long quarantines. Additional analyses for nations outside of Europe could aid in

establishing shorter quarantines that induce higher compliance. Furthermore, following country-specific and individualized quarantion durations could free up resources that could then be better utilized to improve compliance with measures such as providing low-cost, safe accommodations and convenient, rapid, and accurate testing.

Sufficient quarantine durations were calculated to limit infections from COVID-19 entering the country based on reported case numbers within the country. Unfortunately, reporting is not uniform, and under-reporting of a disease with high asymptomaticity is rampant [43–46]. In part for this reason, the EU Traffic Lights system elevates their assessment of risk for countries that have high rates of test positivity. Another approach that could be implemented within the framework presented here would be to adjust COVID-19 incidence estimates for under-reporting. Using a separate model to infer actual daily incidence [46,47], one can integrate adjusted estimates of prevalence into our model framework. In this way, quarantine durations could also depend on country testing rates in addition to reported prevalence.

There is some controversy as to whether antigen testing can substitute for RT-PCR testing [48–50]. On the one hand, antigen tests provide quicker turnaround time and lower cost than RT-PCR tests, and are both logistically easier to perform. On the other hand, antigen tests have lower sensitivity, a higher false-positive rate, and may result in missed cases—especially early in infection when cases are asymptomatic, yet are now or will soon to be highly transmissible. However, the primary differences in sensitivity can be accounted for by incorporation of the sensitivity of the tests along the disease time course, as we have done in our analysis. Our results show that antigen tests can play a significant role in effective quarantine and testing. Except when the prevalence ratio was high between origin (Dark Red status) and destination (Green) country, the sufficient quarantine duration was the same as when a RT-PCR test was used on exit. A major reason for the relatively successful role that rapid antigen tests could play is the faster turnaround that is typical for obtaining the test result. This faster turnaround permits its use as much as a day or more later in quarantine than the RT-PCR test, a beneficial feature that enables its timing just before travel departure in cases wherein the diagnostic sensitivity is still increasing in the early phases of infection [8]. We also showed that multiple rapid antigen tests could potentially be equivalent to or better than RT-PCR tests for prevention of post-quarantine transmission during travel. Furthermore, use of an antigen test does not preclude one from sampling variants of concern—both true positives and false positives can be referred for RT-PCR validation or genetic sequencing.

Our country-specific analysis of sufficient duration of travel quarantine was predicated on travel volumes quantified by data mostly from 2019. Pre-pandemic travel is bound to be an overestimate of the current amount of travel [51], because of pandemic-related concerns regarding exposure, because of unwillingness to pay quarantine-associated or test-associated costs, or because of disinterest in or unavailability to undergo required quarantines. Lower levels of travel will decrease between-country transmission, further limiting the public health impact of international travel quarantine and testing on imminent infections and hospitalization. However, reductions in the absolute travel flow applied uniformly across countries would likely not affect the sufficient quarantine durations we have calculated, which are tied to obtaining no additional transmission beyond what would be occurring with travel prohibition, not tied to any specific public health goals. Quarantine durations will be impacted if changes to 2019 travel flow are asymmetric between the two countries. A high influx of travellers into a country with very little outflow would entail a longer quarantine duration to compensate for the net import of imminent infections. A consequence of the effect of asymmetry of travel flow is that an alternate approach toward ensuring that travel does not increase in-country transmission is to restrict the number of travellers into the country instead of quarantining travellers. This approach could serve effectively alongside travel quarantine, in countries that typically attract a high influx of travellers relative to the travel engaged in by their residents.

Our analytical approach conservatively assumes a long duration of stay—long enough for the prevalence of infection in travelers to approach the prevalence of infection in the visited country. Quarantine policy could be even more targeted, by accounting for traveller length of stay abroad. Using country-specific distributions for the durations of stay of travellers, our analytical approach could be adjusted to specify sufficient quarantines for each duration of stay. Incorporating individualized duration of stay would permit shorter quarantines for individuals travelling for a short-term trip, and require longer quarantines for those planning longer trips that could involve more transmission. However, such a quarantine policy would require more detailed travel information and would be logistically challenging to implement. Moreover, quarantine durations dependent on duration of stay will approach the estimates determined by our analysis, as the duration of stay increases.

The quarantine durations were determined to limit infections from COVID-19 entering the country based on reported case numbers within the country. However, the framework presented here can be used with COVID-19 incidence estimates corrected for under-reporting as well as applied outside the COVID-19 pandemic setting. Using a separate

model to infer actual daily incidence, one can integrate these numbers corrected for under-reporting into our model framework. Thus, quarantine durations may also depend on country testing rates in addition to reported prevalence. The framework can also be used for other identifiable emerging infectious diseases that can be controlled with quarantine, provided there is sufficient information pertaining to the transmissibility over the course of disease and epidemiological periods (e.g., incubation period) to determine the average number of infections after quarantine. Therefore, the framework presented here has broad and flexible application not only to the current pandemic, but also future epidemic threats.

Our analytical approach to determining sufficient quarantines was designed to address the global COVID-19 pandemic. However, the model can be reparameterized with the dynamic infectiousness, sensitivity to testing, and other properties of other emerging diseases that may carry a global risk, to obtain policies of quarantine and testing that are sufficient to prevent increased in-country transmission in the context of global spread. Country borders would be specified to be closed during very early stages of pandemic spread, strictly controlling the quantity of travel associated with the epicenter. Border closure can markedly limit the global dissemination of the virus in the early stages [52], but has provided little demonstrated benefit once transmission becomes established in the country [3]. As the trajectory of a pandemic continues to unfold and country-specific prevalence, circulation of VOCs, and potentially vaccination coverage changes, travel quarantine strategies can be adjusted to assure equitable and safe international travel conditions between countries. In the unfortunate case of global spread, quarantines can be managed to prevent an increase in in-country transmission because of travel, as well as to enable effective and judicious response to new genetic variants of pandemic disease.

Methods

Infectivity profile

Our infectivity profile was based on 77 transmission pairs of COVID-19 cases from the computational code provided by He et al [53,54], specifying a latent period of 2.9 days and an incubation period of 8.29 days [8,13,14]. An age specified proportion p_A of infections remains asymptomatic after the incubation period [10], with those exhibiting symptoms isolating and no longer producing infections. The duration of infectivity is 20 days after symptom onset [55–57], after which we specify the infectivity to be zero. A basic reproductive number of 2.5 was assumed [8], which

reduced to an average of 2.1 when considering isolation upon symptom onset (based on the average age structure in Europe).

COVID-19 test diagnostic sensitivity

We use a similar methodology to Hellewell et al [58] to infer the temporal diagnostic sensitivity of the RT-PCR assay over the course of disease by fitting the diagnostic sensitivity curve of the RT-PCR assay to the results from serial testing (Supplementary Methods).

Country epidemic profile

We utilized the reported daily incidence of a country to determine the fractional incidence and prevalence. We specify prevalence to be infections that are active and not isolated. The estimates of prevalence are detailed under the section *Vaccination, prevalence and hospitalization*. Seroprevalence estimates were used to determine the proportion of the population that is recovered and immune [15], and vaccine coverage determined vaccine-acquired immunity [12]. Those recovered or actively infected were assumed to vaccinate at equal frequency to those never infected.

Long-term travel quarantine

With no travel. Country-specific imminent infection in country A with no travel from country B to country A is

$N_T c_A R_A \left(1 - \varphi_A \right)$, where N_T is the total population of country A, c_A is the fractional incidence per day within country A, R_A is the effective reproduction number including non-immunological public health measures, and φ_A is the percent of country A that is immune. The term φ_A can be decomposed into the fraction who are currently infected plus the fraction that have either recovered from infection and remain immune or have been vaccinated and remain immune.

With only long-term travel to country B and return to country A. Country-specific imminent infection in country A with long-term travel is composed of non-travelers and travelers. The daily contribution to imminent infection of non-travelers

is $N_A c_A R_A(1 - \varphi_A)$, where N_A is the number of non-traveling and non-quarantined country-A residents. At steady-state,

the daily contribution to imminent infection of returning travelers is $n_{A,B} \rho_B R_{Q_A,V}(1 - \varphi_A)$, where $n_{A,B}$ is the daily

number of country-A residents returning from a long-term visit to country B, ρ_B is the prevalence of non-isolated

infections in country B, and $R_{Q_A,V}$ is the average 'left-over' imminent infection in country A of an infected visitor who

underwent the quarantine-and-testing regime Q_A. Simultaneously, the departure of infected individuals decreases

imminent infection by $n_{A,B} \rho_A R_V(1 - \varphi_A)$, where R_V is the average 'left-over' imminent infection of an infected visitor to

country A leaving at an unknown time in their infection period. The details of computing R_V and $R_{Q_A,V}$ are described in

Supplementary Materials. Therefore, permitting the population in country A to perform long-term travel to and return

from country B is no worse than border closure in terms of daily imminent infection when

$$N_T c_A R_A(1 - \varphi_A) \geq N_A c_A R_A(1 - \varphi_A) - n_{A,B} \rho_A R_V(1 - \varphi_A) + n_{A,B} \rho_B R_{Q_A,V}(1 - \varphi_A) . \qquad (1)$$

A sufficient quarantine to ameliorate transmission in country A from long-term travel to country B and return to country

A, and long-term travel to country A from country B. Country-specific imminent infection in country A with long-term

travel is also increased by travelers from country B, whose contribution is $n_{B,A} \rho_B R_{Q_A,V}(1 - \varphi_A)$, where $n_{B,A}$ is the daily

number of long-term visitors from country B to country A. Country-specific imminent infection in country A with

long-term travel is also increased by travelers from country B infected in country A, whose contribution is

$n_B c_A \left(\frac{1-\varphi_B}{1-\varphi_A}\right) R_A(1 - \varphi_A)$, where n_B is number of residents of country B abroad in country A, and $\frac{1-\varphi_B}{1-\varphi_A}$ is the infection

risk ratio for individuals who are not immune to infection at frequency $1 - \varphi_B$ while in country A with its frequency of

susceptibility $1 - \varphi_A$. Simultaneously, the departure of infected individuals from country B decreases imminent infection

by $n_{B,A} \rho_A \left(\frac{1-\varphi_B}{1-\varphi_A}\right) R_V(1 - \varphi_A)$. Therefore, permitting the population in country A to perform long-term travel to and

return from country B, as well as permitting long-term travel from country B to country A, is no worse than border closure in terms of daily imminent infection when

$$N_T c_A R_A \left(1 - \varphi_A\right) \geq$$

$$N_A c_A R_A \left(1 - \varphi_A\right) + n_B c_A \left(\frac{1 - \varphi_B}{1 - \varphi_A}\right) R_A \left(1 - \varphi_A\right) \tag{2}$$

$$- n_{A,B} \rho_A R_V \left(1 - \varphi_A\right) + n_{A,B} \rho_B \left(\frac{1 - \varphi_A}{1 - \varphi_B}\right) R_{Q_A,V} \left(1 - \varphi_A\right) + n_{B,A} \rho_B R_{Q_A,V} \left(1 - \varphi_A\right) - n_{B,A} \rho_A \left(\frac{1 - \varphi_B}{1 - \varphi_A}\right) R_V \left(1 - \varphi_A\right) .$$

Countries may wish to impose the least egregious quarantine-and-testing approach Q_A that satisfies this condition.

Travel quarantine strategies

For our base case, we evaluated a travel quarantine strategy of 0–14 days quarantine duration with RT-PCR test conducted on exit. With the exception of zero-day quarantine, a delay of 24 h was assumed in obtaining results for an RT-PCR test (e.g. an RT-PCR test is conducted 24 h before exit from quarantine). We consider three alternative quarantine strategies: i) no testing, ii) antigen test on exit from quarantine, and iii) antigen test on entry to and exit from quarantine. The sensitivity of the rapid antigen test was informed by the diagnostic sensitivity of the RT-PCR test and the percent positive agreement of the BD Veritor rapid antigen test [59]. For the rapid antigen test, we specify no delay in obtaining the test result. In addition, we examine the sensitivity of our results to the diagnostic sensitivity curve by calculating the minimum travel quarantine duration with an RT-PCR test with diagnostic sensitivity specified by the approach from Wells et al [8]. When evaluating median quarantine durations across sets of country pairs for any of our results, a value associated with "prohibition of travel" was accounted for, and was specified to be longer than 14 days.

Vaccination, prevalence and hospitalization

We assume that vaccination coverage initiates within the elderly age group (≥80) and ends in the youngest age group (0–19).We specify age- and dose-specific efficacy in the reduction of documented infection ($\varepsilon_{a,j}$) to determine the level of vaccine-acquired immunity. Specifying uniform natural immunity (r) across age groups, age-specific prevalence of non-isolated infections was estimated based on the level of natural and vaccine-acquired immunity within all age classes (Supplementary methods). Specifying a vaccine coverage $\nu_{a,1}$ for the first dose, and an coverage of $\nu_{a,2}$ for the second dose in age class a, the proportion of age class a who are immune to infection is specified as

$$\varphi_a = \left(1 - r - \rho_a\right) \cdot \left(\varepsilon_{a,1}\nu_{a,1} + \varepsilon_{a,2}\nu_{a,2}\right) - r - \rho_a. \tag{3}$$

We utilize age-specific hospitalization probabilities estimated from the epidemic in France [60], the age demographics, and age-dependent efficacy in reduction of hospitalizations ($\omega_{a,j}$) to estimate the hospitalization rate (Supplementary methods). Specifying the age specific proportion of infections being hospitalized Ψ_a and the number of imminent infections I_a in age class a, the overall number of hospitalizations is

$$H = \sum_{a=1}^{A} \Psi_a \cdot I_a. \tag{4}$$

Since this measure is at an absolute daily scale, we divide by the population size (N_T) and multiple by 14 and 100,000 to obtain the two week hospitalization rate per 100,000.

Variants of concern

Our analytical approach can naturally incorporate variants of concern as independent factors to control. To demonstrate this flexibility, we incorporated two known variants of concern, B.1.1.7 and 501Y.V2, in an additional analysis. We consider increased transmission of the VOC relative to the wild-type, 100% cross-immunity, and no reduction in vaccine efficacy. The B.1.1.7 VOC has been estimated to be up to 82% more infectious than previous strains [7,61,62] , where 501Y.V2 has been estimated to be 50% more transmissible [7]. Current studies have highlighted reduction in neutralization for the VOC in regards to immunity, but it is not clear how much this reduced neutralization translates to reduction in the efficacy of the vaccine. These components can be integrated as more information about immunity and VOC appear. The assumption of 100% cross immunity also pertains to limited information of the

proportion of the population previously infected with the VOC. We obtained the frequency of these two variants based on genetic surveillance [31]. The accuracy of the frequency of the VOC obtained from the data is limited by the country's frequency of genetic analysis of the samples. When considering multiple variants of concern, the sufficient duration of travel quarantine was defined as the duration that satisfies the imminent infection in equality for all variants considered.

Generalized Approach

For generalized implementation of our modeling framework, we classified a country's status based on the EU traffic-light system, utilizing the age demographics of Europe [63]. Based on the number of new cases in the past 14 days, a country's risk was stratified into Green (25/100,000), Amber (150/100,000), Red (500/100,000) and Dark Red (1,000/100,000). Given a vaccination coverage in the destination country of travel and risk category of origin country of travel, we computed optimal duration of travel quarantine using the inequality for imminent infections (Eq. 2) with a RT-PCR test on exit from quarantine. To adapt our approach to the limited policy-relevant input currently incorporated into the EU traffic-light system—two-week caseload per capita and percentage of positive tests—we assumed that the vaccination coverage in the origin country is the same as that in the destination country, and specified all parameters other than vaccine coverage and age demographics to be that of the average of the 31 European countries from our country-specific data, so that the population size of the origin country and the destination country were 24.5 million, the population travelling each day was 2452, the average duration of stay was four days, $r = 0.188$, such that 18.8% of the destination population possessed natural immunity based on recovery from infection, and 17.6% vaccination coverage.

Daily fractional incidence (c) was calculated by averaging over two weeks of daily cases (e.g., (25 cases / 100,000 people) / 14 days). Considering duration of infection was specified to be 28.29 days and assuming a constant daily incidence, the estimated prevalence of non-isolated infections was calculated as $c(8.29 + 20p_A)$. For our baseline analysis, we specified a vaccine coverage of 10%. To examine the effect of the vaccine coverage on the minimum duration of quarantine, we varied vaccination coverage between 0–100%. We assumed a single vaccine efficacy based on reduction in transmission and reduction in hospitalization from time of initial vaccine to the end of follow-up [11] (**Table S5)** to

attain a generalized efficacy for individuals receiving either one dose or two doses, as to consider all scenarios of coverage of a second dose would be computationally intensive.

We also calculated hospitalization rates in the destination country under each scenario. Irrespective of their current risk category, the destination country was considered to want to keep their hospitalization rates consistent with the lowest risk category (Green). Therefore, we specified this threshold to be the rate of hospitalization for a destination country in Green status with 0% of vaccination coverage and no travel. We then calculated the minimum quarantine duration and resulting hospitalization rates using this alternative threshold and compared it with the corresponding results obtained using imminent infections threshold.

Author contributions: CRW and JPT contributed equally to this work. JPT conceived and designed the study. JPT developed the theory with contributions from CRW and AP. CRW and WC assembled relevant data. CRW wrote computational code, and executed analyses with contributions from AP. All authors contributed to interpretation of results. CRW, AP, and JPT drafted the manuscript. MF and APG contributed to revision of the manuscript. All authors approved the final version of the manuscript.

Competing interests: JPT and APG declare the following competing interests: received funding from an airline company to conduct research on travel quarantine durations. CRW, AP, WC, and MCF declare no competing interest.

Acknowledgements: JPT and APG gratefully acknowledge research funding from EasyJet. JPT gratefully acknowledges funding from the Elihu endowment and the Notsew Orm Sands Foundation. APG gratefully acknowledges funding from the Burnett and Stender families' endowment and the Notsew Orm Sands Foundation.

Table 1. Parameter descriptions and references for determination of sufficient durations of travel quarantine

Parameter	Definition	Reference
N_T	Country population size	[15]
N_A	The number of non-traveling and non-quarantined country-A residents	[15,17–27]
n_B	The number of residents of country B abroad in country A	[17–27]
n_{AB}	The daily number of country-A residents returning from a long-term visit to country B	[17–27]
R_A	Average imminent infection in country A	[8]
$R_{Q_A V}$	Average 'left-over' imminent infection in country A of an infected person who underwent the quarantine-and-testing regime Q_A	[8]
R_V	Average 'left-over' imminent infection of an infected individual in country A leaving at an unknown time in their infection period.	[8]
c_A	Daily fractional incidence in country A	[15]
ϱ_A	Prevalence of non-isolated infections in country A	[15]
r_A	Proportion recovered in country A	[15]
v_A	Proportion of the population receiving at least one dose of the vaccine	[12]
φ_A	Proportion of the population immune to infection	[11,12,15]
p_A	Proportion of infections that are asymptomatic	[10]

Supplementary material: Sufficient strategies for travel quarantine and testing

Supplementary methods

Long-term travel quarantine

We summarize the terms of the inequality for the imminent infections (Eq. 2 in Methods) using indexed symbols (**Table S4**). Specifically, we simplify the different terms of the expressions to reflect age-dependent disease characteristics using $\lambda_{k,j}$ to denote the kth term for age class j (**Table S4**). Accounting for age-dependent disease characteristics, we can specify the inequality as

$$\sum_{j=1}^{X}\left(1-\varphi_A\right)\lambda_{0,j} \geq \sum_{j=1}^{N}\left(1-\varphi_A\right)\left(\lambda_{1,j}+\lambda_{2,j}-\lambda_{3,j}+\lambda_{4,j}+\lambda_{5,j}-\lambda_{6,j}\right).$$

Specifying that $\theta_{k,i}$ proportion of infections are of variant k in country i, portion of the entire population immune to the infection $\varphi_{i,k} = \sum_{j=1}^{A} w_{i,j}\varphi_{i,k,j}$, increasing transmission by factor τ_i, the inequalities determining the number of imminent infections in or destination country i when interacting with origin country m is

$$\sum_{j=1}^{A}(1+\tau_k)(1-\varphi_{k,i})\theta_{k,i}\cdot\lambda_{0,j} \geq \sum_{j=1}^{A}(1+\tau_k)(1-\varphi_{k,i})\left(\theta_{k,i}\lambda_{1,j}+\theta_{k,i}\lambda_{2,j}-\theta_{k,i}\lambda_{3,j}+\theta_{k,m}\lambda_{4,j}+\theta_{k,m}\lambda_{5,j}-\theta_{k,i}\lambda_{6,j}\right)\forall k.$$

Specifically, the minimum travel quarantine travel duration is the period in which all inequalities for the variants of interest are satisfied (i.e. the maximum of all the minimum travel quarantine durations). For our analysis on the variants of concern, we evaluate B.1.1.7, 501Y.V2, and generalized transmission by non-B.1.1.7 non-501Y.V2 strains. In this analysis, we specify the proportion of infections of the wild-type variant to be $\theta_{1,i} = 1 - \theta_{2,i} - \theta_{3,i}$.

Effective reproduction number

A proportion of infections p_A will remain asymptomatic over the entire disease time course t_E, where $1 - p_A$ infections will develop symptoms t_S days post-infection. Once an individual exhibits symptoms, they are assumed to self-isolate and to no longer transmit the disease. To indicate the appearance of symptoms post infection, we use a binary step function,

$$H(t) = \begin{cases} 0, & t < t_S, \\ 1, & t \geq t_S \end{cases},$$

where $f(t)$ is the infectivity over the course of the disease and t_E is the duration of the disease. We denote the infectivity over time

$$r(t) = \begin{cases} R_0 f(t), & t \leq t_E, \\ 0, & t > t_E, \end{cases}.$$

The average number of secondary infections in the absence of self-isolation is

$$R_0 = \int\limits_0^\infty r(t)\ dt.$$

For an asymptomatic individual, the transmission over time is $r_A(t) = r(t)$. To model the isolation of infected individuals for whom symptoms manifest, we denote their transmission over time as $r_S(t) = r(t) \cdot (1 - H(t))$.

For a soon-to-be symptomatic case from the time of infection until the time they develop symptoms, we calculate the effective reproductive number

$$R_{Sym} = \int\limits_{t=0}^\infty r_S(t)dt = \int\limits_{t=0}^{t_S} r(t)dt.$$

For asymptomatics from the time of infection until the end of the disease time course, we calculate the effective reproduction number

$$R_{Asym} = \int\limits_{t=0}^\infty r(t)dt.$$

Thus, the effective reproduction number including non-immunological public health measures in country A is

$$R_A = (1 - p_A)R_{Sym} + p_A R_{Asym}.$$

Unknown time of infection

Quarantine and testing

We model individuals as entering quarantine randomly over the period in which they do not exhibit symptoms. The diagnostic sensitivity of a test at time t is denoted $s(t)$. Individuals who are showing symptoms are not eligible for quarantine and instead are placed in isolation. For a specified duration of quarantine (q), delay in obtaining test result (d_t) and testing occurring over the course of quarantine (t_i), the expected post-quarantine transmission for a soon-to-be symptomatic case is who is tested for disease at any time $0 \le t_n \le q - d_t$ is

$$R_{Sym,Q,V}(q) = \frac{1}{t_S} \int_{u=0}^{t_S} \int_{t=q}^{\infty} r_S(t + u) \cdot \prod_{n=1}^{N} \left(1 - s(t_n + u)\right) dt\, du.$$

For asymptomatic carriers,

$$R_{Asym,Q,V}(q) = \frac{1}{t_E} \int_{u=0}^{t_E} \int_{t=q}^{\infty} r(t + u) \cdot \prod_{n=1}^{N} \left(1 - s(t_n + u)\right) dt\, du.$$

Therefore, the expected post-quarantine transmission is

$$R_{Q_A V}(q) = (1 - p_A)R_{Sym,Q,V}(q) + p_A R_{Asym,Q,V}(q).$$

Some individuals travelling abroad will be infectious and will no longer contribute to transmission within the country. The remaining amount of transmission for these individuals is analogous to a zero-day quarantine with no test. The expected remaining transmission for a soon-to-be symptomatic case is

$$R_{Sym,V} = \frac{1}{t_S} \int_{u=0}^{t_S} \int_{t=0}^{\infty} r_S(t + u) dt\, du.$$

For asymptomatic carriers,

$$R_{Asym,V} = \frac{1}{t_E} \int_{u=0}^{t_E} \int_{t=0}^{\infty} r(t + u) dt\, du.$$

Therefore, the expected remaining transmission for infected travellers is

$$R_V = (1 - p_A)R_{Sym,V} + p_A R_{Asym,V}.$$

Temporal diagnostic sensitivity of an RT-PCR test

To determine the diagnostic sensitivity of the RT-PCR assay, we use serial testing data conducted within the healthcare setting [58]. We use a similar methodology as Hellewell et al [58] to infer the diagnostic sensitivity. However, unlike Hellewell et al [58], we specified the diagnostic sensitivity function to be dependent on the infectivity, $f(t)$, (a proxy for the viral load) instead of only time. Specifically, the probability the RT-PCR test is positive (i.e. diagnostic sensitivity) at time t is expressed as

$$s(t) = f(t)^n / \left(f(t)^n + K \right),$$

where n is the Hill coefficient and K is a saturation constant to be estimated in the fitting.

Data from Hellewell et al [58] specifies whether or not the individual exhibited symptoms on the testing date, the outcome of the self-administered nasal RT-PCR test, as well as the Ct value. Hellewell et al [58] used the serology testing to obtain a subset of 27 healthcare workers who seroconverted during the study period. To determine the shape of the diagnostic sensitivity curve of the RT-PCR assay (**Fig. S20**), we aim to maximize the log-likelihood

$$L = L_T + L_P$$

where L_T is the log-likelihood for the time of infection and L_P is the log-likelihood of the result of the RT-PCR test.

The methodology specified by Hellewell et al [58], accounts for the censoring of symptoms between the testing time to determine the time of infection. Given the date at which they were last asymptomatic (t_i^L) and the time of in which they are first symptomatic (t_i^F) for the N individuals, the log-likelihood for the time of infection is

$$L_T = \sum_{i=1}^{N} \log\left(F(t_i^F - T_i) - F(t_i^L - T_i) \right),$$

where F is the cumulative distribution of the incubation period specified by Qin et al [13]. We specify the upper bound of the time of infection to be the minimum time of the first positive test, the first day of symptoms, and the first day of a non-zero cycle threshold. The lower bound is assumed to be a month prior to the data-driven upper bound.

For the specified diagnostic sensitivity of the test for all individuals and M_i tests for individual i, the likelihood for

the test result is expressed as

$$L_P = \sum_{i=1}^{N} \sum_{j=1}^{M_i} \log\!\left(s(x_{i,j})^{T_{i,j}}(1 - s(x_{i,j}))^{1-T_{i,j}}\right),$$

where $T_{i,j}$ indicates the result of test j for individual i.

Temporal diagnostic sensitivity of a rapid antigen test

The diagnostic sensitivity of the rapid antigen test is expressed as the product of the diagnostic sensitivity of the RT-PCR and the percent positive agreement of the rapid antigen test with an RT-PCR test. For the rapid antigen test, we utilized percent positive agreement data for BD Veritor [59]. We model the percent positive agreement at time t post infection for the rapid antigen test using a linear logistic model

$$\ln\!\left(\frac{p(t)}{1-p(t)}\right) = \beta_0 + \beta_1 t.$$

We fit the model to the data by maximizing the log-likelihood

$$L = \sum_{i=1}^{N} \log\!\left(p(t_i)^{S_i}(1 - p(t_i))^{F_i}\right),$$

where S_i is the number of successes at time point t_i and F_i is the number of failures. We specify that $\beta_1 < 0$ such that the percent positive agreement declines with respect to time during the optimization. However, the data for the percent positive agreement does not include the temporal dynamics prior to symptom onset. To infer the percent positive agreement during the incubation period, we construct a mapping between the viral load and the percent positive agreement post-symptom onset.

Vaccination, prevalence and hospitalization

We utilize age specific hospitalization probabilities estimated from the epidemic in France [60] and the age demographics of Europe [63]. We assume that vaccination coverage initiates at the elderly age group ($\geq$80) and ends in the youngest age group (0–19). The country specific vaccination coverage is that reported for April 12, 2021 [12] Specifying a vaccine coverage of v(i.e. have received at least one dose), the proportion of the age class vaccinated is

$$v_a = \left(v - \sum_{i=1}^{a-1} n_i\right)\!\Big/n_a,$$

the proportion to receive the full two doses is

$$v_{a,2} = \left(v_2 - \sum_{i=1}^{a-1} n_i\right)/n_a,$$

and the proportion of the population to receive one dose is $v_{a,1} = v_a - v_{a,2}$, where n_a is the fraction of the population in age class a.

We utilize age specific vaccine efficacy in the reduction of documented infection (ε) and hospitalizations (ω), stratified by dose [11]. Specifying uniform natural immunity across age groups, the proportion of the population that has vaccine acquired immunity to infection is $\varepsilon_1 v_{a,1}(1-r)+\varepsilon_2 v_{a,1}(1-r)$. Using this the level of natural and vaccine-acquired immunity within an age class, the cumulative number of infections over the past t days within age class a is

$$\overline{I_a}(t) = \overline{I_T}(t) \cdot w_a \cdot \left(1 - (1-r) \cdot \left(\varepsilon_{a,1} v_{a,1} + \varepsilon_{a,2} v_{a,2}\right) - r\right)/ \sum_{j=1}^{X} w_j \cdot \left(1 - (1-r) \cdot \left(\varepsilon_{j,1} v_{j,1} + \varepsilon_{j,2} v_{j,2}\right) - r\right),$$

where w_a is the proportion of the population in age class a, and $\overline{I_T}(t)$ is the cumulative number of infections over the past t days in the whole population. Specifying $p_{A,a}$ proportion of infections are asymptomatic in age class a, the prevalence of non-isolated active infections capable of transmission in age class a is

$$\rho_a = \left((1 - p_{A,a}) \cdot \overline{I_a}(t_S) + p_{A,a} \cdot \overline{I_a}(t_E)\right)/(w_a \cdot N_T).$$

With incidence data being at the daily time scale and an incubation period of 8.29 days, we specify the age based prevalence of non-isolated cases to be

$$\rho_a = \left((1 - p_{A,a}) \cdot \overline{I_a}(8) + p_{A,a} \cdot \overline{I_a}(28)\right)/(w_a \cdot N_T).$$

Therefore, the proportion of age class a who are immune to infection is specified as

$$\varphi_a = \left(1 - r - \rho_a\right) \cdot \left(\varepsilon_{a,1} v_{a,1} + \varepsilon_{a,2} v_{a,2}\right) + r + \rho_a.$$

Specifying the age specific probability of hospitalization h_a and uniform proportion of natural immunity, the age specific proportion of infections being hospitalized is

$$\Psi_a = h_a\left(1 - \left(1 - r - \rho_a\right)v_a - r_a - \rho_a + \left(1 - r - \rho_a\right)\left((1 - \varepsilon_{a,1})(1 - \omega_{a,1})v_{a,1} + (1 - \varepsilon_{a,2})(1 - \omega_{a,2})v_{a,2}\right)\right)/(1 - \varphi_a)$$

For a specified quarantine strategy, the number of imminent infections in age class is

$$I_a = w_{A,j} \cdot (1 - \varphi_{A,j}) \cdot \sum_{j=1}^{N} \left(\lambda_{1,j} + \lambda_{2,j} - \lambda_{3,j} + \lambda_{4,j} + \lambda_{5,j} - \lambda_{6,j} \right).$$

Thus, the overall number of hospitalizations is

$$H = \sum_{a=1}^{A} \Psi_a \cdot I_a.$$

Since this number of hospitalization is quantified on an absolute daily scale, we divide by the population size (N_T) and multiple by 14 and 100,000 to obtain the hospitalization rate per 100,000.

Estimating the population abroad

Within the calculation of imminent infections for a specified travel quarantine, we require the number of travellers who are abroad. To obtain these estimates, we utilize the average duration of stay d_{AB}, the fraction of the total population travelling per day m_{AB}, and the duration of quarantine for our analysis pertaining to long-term travel quarantine.

The daily number of country-A residents leaving for a long-term visit to country B is $n_{A,B} = m_{AB} \cdot N_{T,A}$, where $N_{T,A}$ is the population size of country A and m_{AB} is the proportion of the total population travelling each day. Since travel is assumed to be constant and in steady state, the daily number of country-A residents returning for a long-term visit to country B is equal to the daily number of country-A residents leaving for a long-term visit to country B.

The number of residents of country A abroad in country B is $n_A = m_{AB} \cdot d_{AB} \cdot N_{T,A}$, whereas the number of non-traveling and non-quarantined country-A residents for a specified quarantine q_A is $N_A = N_{T,A}(1 - m_{AB} \cdot (d_{AB} + q_A))$. We consider only the quarantine duration of the destination country (q_A), as the choice of quarantine is independent of the paired countries strategy. Thus, specifying no quarantine for the origin country provides a conservative estimate of the duration of quarantine specified by the destination country.

Supplementary Figures

Figure S1. The estimated minimum duration of travel quarantine with an RT-PCR test on exit for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with an RT-PCR test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Figure S2. Sensitivity of the minimum travel quarantine duration to changes in parameters. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the change in the minimum duration of travel quarantine with an RT-PCR test on exit that should be stated by the destination country for individuals arriving from the origin country when **A**) prevalence in the destination country, **B**) proportion of the population travelling from the destination country to the origin, **C**) proportion of the population travelling from the origin country to the destination, **D**) prevalence in the origin country, **E**) fractional incidence in the destination country, **F**) duration of stay in destination, **G**) natural immunity in origin, **H**) duration of stay in origin, **I**) natural immunity in the destination country **J**), vaccine immunity in the destination country **K**), vaccine immunity in the origin country **L**) age demographics in the destination country, **M**) age demographics in the origin country, **N**) the $\log_{10}$ populations size of the origin country, and **O**) the $\log_{10}$ population size in the destination country is moved one standard deviation towards the median of the 31 countries while other parameters remain fixed. The far-left bin of the histogram denotes when border closure is lifted due to the change in parameter (i.e. baseline specifies border closure and perturbation allows for travel) and the far-right bin specifies the addition of border closure (i.e. baseline allows for travel and perturbation results in border closure). We stratify the changes in quarantine by when the parameter value increases (blue) and decreases (orange). We also calculated the standard deviation in the change of quarantine duration for no border closure (i.e. no border closure in baseline or from the perturbation; top left). For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Figure S3. The two-week hospitalization rate per 100,000 for a zero-day travel quarantine with an RT-PCR test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two week hospitalization rate (colour gradient) from the estimated imminent infections for a zero-day travel quarantine with an RT-PCR test on exit. Within- country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Figure S4. The two-week hospitalization rate per 100,000 for a zero-day travel quarantine with a rapid antigen test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two week hospitalization rate (colour gradient) from the estimated imminent infections for a zero-day travel quarantine with a rapid antigen test on exit. Within- country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.

Figure S5. The two-week hospitalization rate per 100,000 for a zero-day travel quarantine with a rapid antigen test on both entry and exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two week hospitalization rate (colour gradient) from the estimated imminent infections for a zero-day travel quarantine with a rapid antigen test on entry and exit (i.e. dual test). Within- country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.

Figure S6. The two-week hospitalization rate per 100,000 for a zero-day travel quarantine with no testing. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two week hospitalization rate (colour gradient) from the estimated imminent infections for a zero-day travel quarantine with no test conducted. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000.

Figure S7. The relative decrease in the two week hospitalization rate per 100,000 when extending a zero-day travel quarantine to a 14-day travel quarantine, with an RT-PCR test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with an RT-PCR test on exit to a 14-day travel quarantine with RT-PCR test on exit. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. For travel quarantine durations of 14 days, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Figure S8. The relative decrease in the two week hospitalization rate per 100,000 when extending a zero-day travel quarantine to a 14-day travel quarantine, with a rapid antigen test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with a rapid antigen test on exit to a 14-day travel quarantine with a rapid antigen test on exit. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.

Figure S9. The relative decrease in the two week hospitalization rate per 100,000 when extending a zero-day travel quarantine to a 14-day travel quarantine, with a rapid antigen test on both entry and exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with a rapid antigen test on entry and exit (i.e. dual testing) to a 14-day travel quarantine with rapid antigen test on entry and exit. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.

Figure S10. The relative decrease in the two week hospitalization rate per 100,000 when extending a zero-day travel quarantine to a 14-day travel quarantine, with no testing conducted. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with no testing to a 14-day travel quarantine no testing. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000.

Figure S11. The estimated minimum duration of travel quarantine for specified country pairs that reduces imminent infections to be equivalent to border closure when considering variants of concern. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, percentage of variants of concern, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine (colour gradient) that should be stated by the destination country for individuals arriving from the origin country when considering the wild-type and the variant of concern the variants of concern B.1.1.7. and 501Y.V2. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified quarantine can exceed 14 days). Within- country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result. Please note that the frequency of sampling in some of the countries presented in this Supplementary Figure may not be sufficient enough to adequately assess the level of circulation of the VOCs in the country.

Figure S12. The estimated minimum duration of travel quarantine with no testing for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with no test conducted (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000.

Figure S13. The estimated minimum duration of travel quarantine with a rapid antigen test on exit for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. We assumed that there was no delay in obtaining the test result from a rapid antigen test.

Figure S14. The estimated minimum duration of travel quarantine with a rapid antigen test on entry and exit for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on entry and exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within–country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. There was assumed to be no delay in obtaining the test result from a rapid antigen test.

Figure S15. Comparison between the country-specific quarantine durations and the durations determined from the EU COVID classification system. The estimates for the minimum quarantine duration are stratified by destination country and origin country (*x* axis) for the country-pair analysis (dots; median dashed line) and our tier-based analysis (solid line) for a quarantine with **A**) a RT-PCR test on exit, **B**) no testing conducted, **C**) rapid antigen test on exit, and **D**) a rapid antigen test on both entry and exit. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result and no delay in obtaining the rapid antigen test. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.

Figure S16. The estimated minimum duration of travel quarantine with a RT-PCR test on exit (parameterized with an alternate diagnostic sensitivity curve) for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on entry and exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result. The alternate diagnostic sensitivity curve for the RT-PCR test is that specified previously by Wells et al [8].

Figure S17. The estimated minimum duration of travel quarantine with a rapid antigen test on exit (parameterized by an alternate diagnostic sensitivity curve) for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. We assumed that there was no delay in obtaining the test result from a rapid antigen test. The diagnostic sensitivity of the RT-PCR test, used to determine the diagnostic sensitivity of the rapid antigen test, is that specified previously by Wells et al [8].

Figure S18. The estimated minimum duration of travel quarantine with a rapid antigen test on both entry and exit (parameterized by an alternate diagnostic sensitivity curve) for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on entry and exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 case per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 case per 100,000. There was assumed to be no delay in obtaining the test result from a rapid antigen test. The diagnostic sensitivity of the RT-PCR test, used to determine the diagnostic sensitivity of the rapid antigen test, is that specified previously by Wells et al [8].

Figure S19. The estimated minimum duration of travel quarantine for specified country pairs based on the European Union risk states that reduces imminent infections to be equivalent to border closure for an alternative diagnostic sensitivity curve**.** Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as wells as European demographics, 17.6% vaccine coverage, 18.8% natural immunity, we determine the minimum travel duration of quarantine (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to prohibition of travel (dark purple, i.e., specified quarantine can exceed 14 days) with **A**) an RT-PCR test on exit, **B**) no test, **C**) a rapid antigen test on exit, and **D**) a rapid antigen test on both entry and exit. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result and no delay in obtaining the rapid antigen test. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result. The diagnostic sensitivity of the RT-PCR test used for this figure is that specified previously by Wells et al [8].

Figure S20. The temporal diagnostic sensitivity of a RT-PCR test and rapid antigen test**.** Specifying an incubation period of 8.29 days (vertical gray dashed line) and a latent period of 2.9 days, the **A**) diagnostic sensitivity of an RT-PCR test (represented by a Hill function; black line) that was fit to the empirical data from Hellewell et al [64], **B**) the estimated percent positive agreement for a rapid antigen test (red line) that was fit to the percent positive agreement data for the BD Veritor rapid antigen test [59] (red dots), **C**) the comparison of the diagnostic sensitivity of the RT-PCR test (black line) and rapid antigen test (red line) using the data from Hellewell et al [64] and **D**) the comparison of the diagnostic sensitivity of the RT-PCR test (black line) and rapid antigen test (red line) using the RT-PCR curve specified by Wells et al [8].

Supplementary Tables

Table S1. References for the construction of the travel flow matrix and duration of stay for the 31 countries

Country	Data source	Year	Reference
Austria	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Belgium	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Bulgaria [a]	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Czechia	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Cyprus	TourMIS; Office for National Statistics (UK)	2018 and 2019	[17–19]
Denmark	Office for National Statistics (UK)	2019	[18,19]
Estonia	TourMIS	2018 and 2019	[17]
Finland	TourMIS; Office for National Statistics (UK)	2019	[17–19]
France	Office for National Statistics (UK); Ministry of Economy for France	2019	[18,19,22]
Germany	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Greece	Hellenic Statistical Authority; TourMIS ; Office for National Statistics (UK)	2019	[17–19,23,24]
Hungary	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Republic of Ireland	TourMIS; Failte Ireland; Office for National Statistics (UK)	2019	[17–19,25]
Italy	National Institute of Statistics, Italy; TourMIS; Office for National Statistics (UK)	2019	[17–19,26]
Lithuania	Office for National Statistics (UK)	2019	[18,19]
Luxembourg	Office for National Statistics (UK)	2019	[18,19]
Malta	Office for National Statistics (UK)	2019	[18,19]
Netherlands	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Norway [b]	Statistics Norway; TourMIS; Office for National Statistics (UK)	2019 and 2021	[17–21]
Poland	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Portugal	TourMIS; Office for National Statistics (UK)	2019	[17–19]

Romania	Office for National Statistics (UK)	2019	[18,19]
Russia	Office for National Statistics (UK)	2019	[18,19]
Serbia	Office for National Statistics (UK)	2019	[18,19]
Slovakia	Office for National Statistics (UK)	2019	[18,19]
Slovenia	TourMIS; Office for National Statistics (UK)	2019	[17–19]
Spain	Office for National Statistics (UK)	2019	[18,19]
Sweden	Office for National Statistics (UK)	2019	[18,19]
Switzerland [c]	TourMIS; Office for National Statistics (UK)	2019	[17–19]
United Kingdom	Office for National Statistics (UK)	2019	[18,19]
Turkey [d]	Turkey Statistical Institute; TourMIS; Office for National Statistics (UK)	2019	[17–19,27]

[a] Arrivals determined by "Arrivals of visitors at frontiers", with average duration of stay determined by "Arrivals of visitors at frontiers" and "Bednights in all forms of paid accommodation"

[b]Average duration Norway assumed to be fixed for all countries and based on Jan 2021 travel

[c]Switzerland numbers are based only on arrivals to hotel accommodations, likely underestimating arrivals

[d]Average duration of stay in Turkey is fixed for all countries as there is no country stratified values

Table S2. Parameters describing the epidemic profile of the 31 European countries [a].

Country	Population size	Cases per 100,000 [b]	Prevalence of non-isolated infections per 100,000 [c]	Daily fractional incidence per 100,000	Seroprevalence	Vaccine coverage [d]	Level of vaccine-acquired immunity [e]
Austria	8916185	442	748	21.8	19%	17%	8%
Belgium	11419166	475	818	15.4	20%	17%	7%
Bulgaria	6934625	604	1043	45.0	26%	7%	2%
Cyprus	1313477	536	773	40.2	7%	10%	5%
Czechia	10643487	605	1305	9.3	30%	13%	6%
Denmark	5802733	166	241	8.9	8%	17%	9%
Estonia	1312361	779	1691	20.5	24%	20%	7%
Finland	5534095	106	210	4.1	9%	20%	6%
France	66204315	787	1219	59.1	28%	17%	6%
Germany	84914056	270	414	15.6	11%	16%	7%
Greece	10337172	400	584	15.5	10%	14%	8%
Hungary	9674413	869	1646	52.5	35%	31%	11%
Republic of Ireland	4910357	127	230	7.8	7%	15%	8%
Italy	60313170	389	688	16.2	16%	16%	7%
Lithuania	2794223	444	623	21.8	15%	18%	8%
Luxembourg	618550	454	778	22.3	19%	16%	7%
Malta	439221	165	521	10.7	11%	40%	20%
Netherlands	17156788	598	956	39.2	16%	18%	7%
Norway	5348847	189	345	12.1	4%	16%	8%
Poland	38434445	829	1382	31.3	27%	15%	6%
Portugal	10651263	66	102	2.5	30%	15%	6%
Romania	19237066	354	604	12.1	21%	12%	6%
Russia	146717428	81	136	5.6	16%	6%	3%
Serbia	8746785	625	1138	33.9	18%	20%	12%

Slovakia	5437223	240	479	1.9	25%	16%	6%
Slovenia	2074271	666	1010	13.8	30%	16%	6%
Spain	46021218	219	324	16.8	21%	17%	7%
Sweden	10222546	783	1206	34.0	25%	15%	6%
Switzerland	8775204	304	473	31.3	15%	13%	8%
Turkey	81359693	815	1068	67.1	21%	14%	8%
United Kingdom	67220447	64	139	5.3	18%	48%	18%

[a] The data specified here is for April 12, 2021.

[b] Cases per 100,000 is determined over a two-week period, as specified by the European Union COVID-19 risk stratification

[c] Prevalence of non-isolated infections is a weighted calculation based on the proportion of symptomatic infections and asymptomatic infections, with symptomatic cases isolating on symptom onset. For symptomatic infections, case counts over the last eight days are used to reflect the duration of the incubation period. For asymptomatic infections, case counts used over the last 28 days are used to reflect the duration of disease.

[d] We define vaccination coverage to be the percentage of the population to receive at least one dose of the vaccine

[e] The level of vaccine acquired immunity is dependent on the age-demographics of the country, proportion of the population partially and fully immunizes, as well as age and dose specific vaccine efficacy.

Table S3. The percentage of infections that are attributed to the variants of concern B.1.1.7. and 501Y.V2 [31] [a]

Country	Percentage of cases attributed to VOC B.1.1.7.	Percentage of cases attributed to VOC 501Y.V2
Austria	0.906	0
Belgium	0.799	0.024
Bulgaria	0	N/A
Cyprus	0	N/A
Czechia	0.825	0
Denmark	0	0
Estonia	0	0
Finland	0	0
France	0.525	0.043
Germany	0.909	0.018
Greece	0	N/A
Hungary	0	N/A
Republic of Ireland	0.809	0.007
Italy	0.893	0.001
Lithuania	0.798	0
Luxembourg	0.658	0.289
Malta	N/A	N/A
Netherlands	0.359	0.009
Norway	0.911	0.089
Poland	0.972	0.003
Portugal	0	0
Romania	0.818	N/A
Russia	0	0
Serbia	0	N/A

Slovakia	0.979	0
Slovenia	0.718	0
Spain	0.769	0.021
Sweden	0.969	0.01
Switzerland	0.946	0.009
Turkey	0.041	0.128
United Kingdom	0.976	0.005

[a] These percentages are based on the proportion of cases in the past four weeks based on the data accessed April 23, 2021, which would contain the date of April 12 in Table S2.

Table S4. Definitions of the terms in the inequality for daily imminent infection

Imminent infections	Infection term	Age class j infection term	Abbreviation
Due to border closure between country A and country B	$N_T c_A R_A$	$N_T\left(c_A \cdot \frac{w_{A,j}(1-\varphi_{A,j})}{(1-\varphi_A)}\right) \cdot R_{A,j}$	$\lambda_{0,j}$
From residents of country A who are not travelling and are susceptible to infection	$N_A c_A R_A$	$N_A\left(c_A \cdot \frac{w_{A,j}(1-\varphi_{A,j})}{1-\varphi_A}\right) \cdot R_{A,j}$	$\lambda_{1,j}$
From previously susceptible residents of country B who are currently in country A	$n_B c_A\left(\frac{1-\varphi_B}{1-\varphi_A}\right)R_A$	$n_B \cdot \left(c_A \cdot \frac{w_{B,j}(1-\varphi_{B,j})}{1-\varphi_A}\right) \cdot R_{A,j}$	$\lambda_{2,j}$
From infectious residents of country A who are travelling to country B that need to be removed	$n_{A,B}\rho_A R_V$	$n_{A,B} \cdot w_{A,j} \cdot \rho_{A,j} \cdot R_{V,j}$	$\lambda_{3,j}$
From residents of country A who where infected abroad, have gone through quarantine and are returning to country A	$n_{A,B}\rho_B\left(\frac{1-\varphi_A}{1-\varphi_B}\right)R_{Q_{A'}V}$	$n_{A,B} \cdot w_{A,j} \cdot \rho_{B,j}\left(\frac{1-\varphi_{A,j}}{1-\varphi_{B,j}}\right) \cdot R_{Q_{A'}j}$	$\lambda_{4,j}$
From infectious residents of country B who are travelling to country A and have gone through quarantine	$n_{B,A}\rho_B R_{Q_{A'}V}$	$n_{B,A} \cdot w_{B,j} \cdot \rho_{B,j} \cdot R_{Q_{A'}j}$	$\lambda_{5,j}$
From infectious residents of country B who were infected abroad in country A and are returning to country B that need to be removed	$n_{B,A}\rho_A\left(\frac{1-\varphi_B}{1-\varphi_A}\right)R_V$	$n_{B,A} \cdot w_{B,j} \cdot \rho_{A,j}\left(\frac{1-\varphi_{B,j}}{1-\varphi_{A,j}}\right) \cdot R_{V,j}$	$\lambda_{6,j}$

Table S5. Age-specific parameters used in the travel quarantine analysis

Parameter	Age class								Reference
	0–19	20–29	30–39	40–49	50–59	60–69	70–79	≥80	
Percentage of infections asymptomatic	81.91%	77.59%	77.59%	69.46%	69.46%	64.54%	64.54%	35.44%	[10]
Percentage of infections hospitalization	0.1%	0.5%	1.1%	1.4%	2.9%	5.8%	9.3%	26.2%	[60]
Vaccine efficacy (First dose): Transmission [a]	32%	32%	32%	30%	30%	30%	26%	26%	[11]
Vaccine efficacy (Second dose): Transmission [b]	94%	94%	94%	90%	90%	90%	95%	95%	[11]
Vaccine efficacy (First dose): Hospitalization [c]	33%	33%	33%	70%	70%	70%	51%	51%	[11]
Vaccine efficacy (Second dose): Hospitalization [d]	87%	87%	87%	87%	87%	87%	87%	87%	[11]
Vaccine efficacy (General): Transmission [e]	50%	50%	50%	48%	48%	48%	47%	47%	[11]
Vaccine efficacy (General): Hospitalization [f]	50%	50%	50%	74%	74%	74%	57%	57%	[11]

[a] Reduction in documented infection during the time from 0–27 days after first dose
[b] Reduction in documented infection from 7 days after second dose to the end of follow-up
[c] Reduction in hospitalization from 0–27 days after the first dose
[d] Reduction in hospitalization across all age groups from 7 days after second dose to the end of follow-up
[e] Reduction in documented infection from day 0 to the end of follow-up
[f] Reduction in hospitalization from day 0 to the end of follow-up

Table S6. Parameter descriptions and values used to determine the minimum duration of travel quarantine

Parameter	Definition	Value	Reference
t_S	Incubation period	8.29 days	[13]
t_L	Latent period	2.9 days	[14]
$t_E = t_S + 20$	Duration of disease	28.29 days	[55–57]
R_0	Basic reproductive number	2.5	[8]
N	Population size (EU traffic light analysis)	24.5×10^6	The average population size of the 31 countries
n_{AB} and n_{BA}	Number of travellers each day (EU traffic light analysis)	2452	Based the average proportion of the total population travelling for the different country pairs
r	Natural immunity (EU traffic light analysis)	0.188	The average level of natural immunity among the 31 countries
d_{AB} and d_{BA}	Duration of stay to determine proportion abroad (EU traffic light analysis)	4 days	The average duration of stay among the country pairs
τ	Increase in transmission for B.1.1.7 variant of concern	0.82	[7,61,62]
τ	Increase in transmission for 501Y.V2 variant of concern	0.50	[7]
n	Hill coefficient for the RT-PCR diagnostic sensitivity curve	0.903	Estimated
K	Saturation constant for the RT-PCR diagnostic sensitivity curve	0.038	Estimated
β_0	Logistic regression coefficient for the percent positive agreement curve for the rapid antigen test	5.698	Estimated
β_1	Logistic regression coefficient for the percent positive agreement curve for the rapid antigen test	-0.379	Estimated

References

1. Tognotti E. Lessons from the history of quarantine, from plague to influenza A. Emerg Infect Dis. 2013 Feb;19(2):254–9.

2. Linka K, Peirlinck M, Sahli Costabal F, Kuhl E. Outbreak dynamics of COVID-19 in Europe and the effect of travel restrictions. Comput Methods Biomech Biomed Engin. 2020 Aug;23(11):710–7.

3. Mallapaty S. What the data say about border closures and COVID spread. Nature. 2021 Jan;589(7841):185.

4. Abdulrahman A, AlSabbagh M, AlAwadhi A, Al-Tawfiq JA, Rabaan AA, Atkin S, et al. Quarantining arriving travelers in the era of COVID-19: balancing the risk and benefits a learning experience from Bahrain. Tropical Diseases, Travel Medicine and Vaccines. 2021 Jan 12;7(1):1–3.

5. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020 Apr 24;368(6489):395–400.

6. Wells CR, Sah P, Moghadas SM, Pandey A, Shoukat A, Wang Y, et al. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7504–9.

7. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med [Internet]. 2021 Mar 24; Available from: http://dx.doi.org/10.1056/NEJMc2100362

8. Wells CR, Townsend JP, Pandey A, Moghadas SM, Krieger G, Singer B, et al. Optimal COVID-19 quarantine and testing strategies. Nat Commun. 2021 Jan 7;12(1):356.

9. COVID-19: Border crossing information [Internet]. NSW Department of Industry. 2021 [cited 2021 Mar 10]. Available from: https://www.dpi.nsw.gov.au/home/covid-19/border-crossing-information

10. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Sabatino G, et al. Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy. JAMA Netw Open. 2021 Mar 1;4(3):e211085–e211085.

11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med [Internet]. 2021 Feb 24; Available from: http://dx.doi.org/10.1056/NEJMoa2101765

12. owid. owid/covid-19-data [Internet]. [cited 2021 Apr 15]. Available from: https://github.com/owid/covid-19-data

13. Qin J, You C, Lin Q, Hu T, Yu S, Zhou X-H. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. Sci Adv. 2020 Aug;6(33):eabc1202.

14. Wang X, Pasco RF, Du Z, Petty M, Fox SJ, Galvani AP, et al. Impact of Social Distancing Measures on Coronavirus Disease Healthcare Demand, Central Texas, USA. Emerg Infect Dis. 2020 Oct;26(10):2361–9.

15. COVID-19 estimate downloads [Internet]. 2020 [cited 2021 Apr 15]. Available from: http://www.healthdata.org/covid/data-downloads

16. kieshaprem. kieshaprem/synthetic-contact-matrices [Internet]. [cited 2021 Apr 15]. Available from: https://github.com/kieshaprem/synthetic-contact-matrices

17. MODUL University Vienna, Karl W♦ber. TourMIS [Internet]. [cited 2021 Mar 30]. Available from: https://www.tourmis.info/

18. Travel trends estimates: UK residents' visits abroad - Office for National Statistics [Internet]. [cited 2021 Apr 15]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/leisureandtourism/datasets/ukresidentsvisitsabroad

19. Travel trends estimates: overseas residents in the UK - Office for National Statistics [Internet]. [cited 2021 Apr 15]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/leisureandtourism/datasets/overseasresidentsvisitstotheuk

20. Accommodation [Internet]. [cited 2021 Apr 21]. Available from: http://www.ssb.no/en/statbanken/statbank/table/08401/

21. Accommodation [Internet]. [cited 2021 Apr 21]. Available from: https://www.ssb.no/en/transport-og-reiseliv/reiseliv/statistikk/overnattingar

22. [No title] [Internet]. [cited 2021 Apr 21]. Available from: https://www.entreprises.gouv.fr/files/files/directions_services/etudes-et-statistiques/4p-DGE/2018-07-4p-N84-EVE-version-anglaise.pdf

23. Greece in Figures - ELSTAT [Internet]. [cited 2021 Apr 15]. Available from: https://www.statistics.gr/en/greece-in-figures?p_p_id=com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_mvcPath=%2Fview_content.jsp&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_assetEntryId=17020463&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_type=document

24. Greece in Figures - ELSTAT [Internet]. [cited 2021 Apr 15]. Available from: https://www.statistics.gr/en/greece-in-figures?p_p_id=com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_mvcPath=%2Fview_content.jsp&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_assetEntryId=17069628&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_type=document

25. Website [Internet]. [cited 2021 Apr 21]. Available from: https://www.failteireland.ie/FailteIreland/media/WebsiteStructure/Documents/3_Research_Insights/4_Visitor_Insights/Key-Tourism-Facts-2019.pdf?ext=.pdf

26. OECD. Istat Statistics [Internet]. [cited 2021 Apr 21]. Available from: http://dati.istat.it/?lang=en

27. (tüik) TİK. TÜİK Kurumsal [Internet]. [cited 2021 Apr 13]. Available from: https://data.tuik.gov.tr/Bulten/Index?p=Tourism-Statistics-Quarter-IV:-October-December-and-Annual,-2020-37438

28. Department of Foreign Affairs. EU Traffic Lights Approach - Department of Foreign Affairs [Internet]. [cited 2021 Apr 15]. Available from: https://dfa.ie/travel/travel-advice/eu-traffic-lights-approach/

29. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95–9.

30. Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, et al. Sixteen novel lineages of SARS-CoV-2 in

South Africa. Nat Med. 2021 Feb 2;27(3):440–6.

31. GISAID - hCov19 Variants [Internet]. [cited 2021 Apr 15]. Available from: https://www.gisaid.org/hcov19-variants/

32. McMahon S. How 9 destinations around the world enforce mandatory quarantines. The Washington Post [Internet]. 2021 Feb 2 [cited 2021 Apr 20]; Available from: https://www.washingtonpost.com/travel/2021/02/02/quarantine-hotels-mandatory-covid/

33. Ledsom A. The Promise Of International Travel: April EU Travel Restrictions, Covid-19 Test Requirements, Quarantine By Country [Internet]. Forbes. 2021 [cited 2021 Apr 20]. Available from: https://www.forbes.com/sites/alexledsom/2021/04/15/the-promise-of-international-travel-april-eu-travel-restrictions-covid-19-test-requirements-quarantine-by-country/

34. Chen S, Li Q, Gao S, Kang Y, Shi X. State-specific projection of COVID-19 infection in the United States and evaluation of three major control measures. Sci Rep. 2020 Dec 30;10(1):1–9.

35. Linka K, Rahman P, Goriely A, Kuhl E. Is it safe to lift COVID-19 travel bans? The Newfoundland story. Comput Mech. 2020 Aug 29;66(5):1081–92.

36. de Jong E. New Zealand borders to stay closed until citizens are "vaccinated and protected." The Guardian [Internet]. 2021 Jan 26 [cited 2021 Apr 12]; Available from: http://www.theguardian.com/world/2021/jan/26/new-zealand-borders-to-stay-closed-until-citizens-are-vaccinated-and-protected

37. Reuters. New Zealand's borders may stay shut for most of the year, PM Ardern says [Internet]. CNN; 2021 [cited 2021 Apr 12]. Available from: https://www.cnn.com/2021/01/26/asia/new-zealand-covid-borders-shut-intl-hnk/index.html

38. Yang J, Li J, Lai S, Ruktanonchai CW, Xing W, Carioli A, et al. Uncovering two phases of early intercontinental COVID-19 transmission dynamics. J Travel Med [Internet]. 2020 Oct 22 [cited 2021 Apr 25];27(8). Available from: https://academic.oup.com/jtm/article-pdf/27/8/taaa200/35282391/taaa200.pdf

39. Karatayev VA, Anand M, Bauch CT. Local lockdowns outperform global lockdown on the far side of the COVID-19 epidemic curve. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24575–80.

40. Some travellers at Toronto airport fined for violating Ontario rules [Internet]. CBC. 2021 [cited 2021 Apr 12]. Available from: https://www.cbc.ca/news/canada/toronto/pearson-covid-toronto-airport-1.5927007

41. dgoldfinger. Public Health Agency of Canada "looking into" non-compliance incidents of new travel rules [Internet]. Global News. 2021 [cited 2021 Apr 16]. Available from: https://globalnews.ca/news/7660045/phac-covid-19-quarantine-non-compliance-travellers/

42. [No title] [Internet]. [cited 2021 Apr 25]. Available from: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/publicat/ccdr-rmtc/15vol41/dr-rm41s-6/assets/pdf/15vol41s-6_overview-apercu-eng.pdf

43. Alex Perkins T, Cavany SM, Moore SM, Oidtman RJ, Lerch A, Poterek M. Estimating unobserved SARS-CoV-2 infections in the United States. Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22597–602.

44. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA Netw Open. 2021 Jan 4;4(1):e2033706–e2033706.

45. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology. 2021 Mar 1;27(2):110–5.

46. Noh J, Danuser G. Estimation of the fraction of COVID-19 infected people in U.S. states and countries worldwide. PLoS One. 2021 Feb 8;16(2):e0246772.

47. Wu SL, Mertens AN, Crider YS, Nguyen A, Pokpongkiat NN, Djajadi S, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. Nat Commun. 2020 Sep 9;11(1):1–10.

48. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020 Aug 1;129:104455.

49. Pray IW. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Apr 20];69. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm695152a3.htm

50. Guglielmi G. Rapid coronavirus tests: a guide for the perplexed. Nature. 2021 Feb 9;590(7845):202–5.

51. Air travel down 60 per cent, as airline industry losses top $370 billion: ICAO [Internet]. 2021 [cited 2021 Apr 20]. Available from: https://news.un.org/en/story/2021/01/1082302

52. Kang N, Kim B. The Effects of Border Shutdowns on the Spread of COVID-19. J Prev Med Public Health. 2020 Sep;53(5):293–301.

53. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 May;26(5):672–5.

54. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 Sep;26(9):1491–3.

55. Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in Wuhan, China: A Descriptive Study [Internet]. SSRN Electronic Journal. Available from: http://dx.doi.org/10.2139/ssrn.3548769

56. CDC. Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19 [Internet]. 2021 [cited 2021 Apr 13]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html

57. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13–22.

58. Estimating the effectiveness of routine asymptomtatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections [Internet]. 2020 [cited 2021 Jan 13]. Available from: https://cmmid.github.io/topics/covid19/pcr-positivity-over-time.html

59. Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. J Clin Microbiol [Internet]. 2020 Dec 17;59(1). Available from: http://dx.doi.org/10.1128/JCM.02338-20

60. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020 Jul 10;369(6500):208–11.

61. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science [Internet]. 2021 Apr 9 [cited 2021 Apr 20];372(6538). Available from: https://science.sciencemag.org/content/372/6538/eabg3055.abstract

62. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021 Mar 25;1–17.

63. Population Pyramids of the World from 1950 to 2100 [Internet]. [cited 2021 Apr 20]. Available from: https://www.populationpyramid.net/ europe/2019/

64. Hellewell J, Russell TW, Beale R, Kelly G, Houlihan C, Nastouli E, et al. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections [Internet]. Available from: http://dx.doi.org/10.1101/2020.11.24.20229948